ReviewInternational journal of radiation oncology, biology, physics2021
Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
Review in International journal of radiation oncology, biology, physics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Potential Clinical Significance of Overall Targeting Accuracy and Motion Management in the Treatment of Tumors That Move With Respiration: Lessons Learnt From a Quarter Century of Stereotactic Body Radiotherapy From Dose Response Models.Frontiers in oncology · 2020Pooled it
- Correlation of dosimetric factors with the development of symptomatic radiation pneumonitis in stereotactic body radiotherapy.Radiation oncology (London, England) · 2020Trial
- Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Review
- Translational tumor control probability modeling for NSCLC: A two-dimensional maximum-likelihood framework.Medical physics · 2026Article
- Radiation induces an EGFR-dependent lactate-epigenetic program underlying synergy with EGFR inhibition.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Robustness of Tumor Control Against Intrafraction Patient Motion in Lung Stereotactic Body Radiation Therapy.Advances in radiation oncology · 2026Article
- Internal target volume reproducibility and dose coverage for lung stereotactic body radiotherapy using spine-based positioning and tracking.Physics and imaging in radiation oncology · 2026Article
- Moving towards single fraction peripheral lung stereotactic body radiation therapy: patient care during and after the global COVID-19 pandemic.Lung cancer management · 2025Article
- Integrating Surgery and Ablative Therapies for the Management of Multiple Primary Lung Cancer: A Systematic Review.Cancers · 2025Review
- Development and validation of a nomogram for local control prediction in lung cancer patients treated with stereotactic body radiation therapy based on clinical, dosimetric, and inflammation-related parameters.BMC pulmonary medicine · 2025Article
- Steps towards overcoming challenges in clinical practice at 1.5T MR-Linac for lung cancer adaptive radiotherapy.BMC cancer · 2025Article
- Article
- Optimization of image reconstruction technique for respiratory-gated lung stereotactic body radiotherapy treatment planning using four-dimensional CT: a phantom study.Radiological physics and technology · 2025Article
- Deep learning-based synthetic CT for dosimetric monitoring of combined conventional radiotherapy and lattice boost in large lung tumors.Radiation oncology (London, England) · 2025Article
- Radiation-Induced Lung Injury CT Features: Early Non-Small Cell Lung Cancer SBRT Prognosticators.Current medical imaging · 2025Article
- Histology-driven hypofractionated radiation therapy schemes for early-stage lung adenocarcinoma and squamous cell carcinoma.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2024Article
- Survival analysis after stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a single-institution cohort study.Radiation oncology (London, England) · 2024Article
- Protocol of a phase II study to evaluate the efficacy and safety of deep-inspiration breath-hold daily online adaptive radiotherapy for centrally located lung tumours (PUDDING study).Radiation oncology (London, England) · 2024Article
- The role of online MR-guided multi-fraction stereotactic ablative radiotherapy in lung tumours.Clinical and translational radiation oncology · 2024Article
- Predictive clinical and dosimetric parameters for risk of relapse in early-stage non-small cell lung cancer treated by SBRT: A large single institution experience.Clinical and translational radiation oncology · 2024Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
14 authors.
Funding
Abstract
purposeNumerous dose and fractionation schedules have been used to treat medically inoperable stage I non-small cell lung cancer (NSCLC) with stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy. We evaluated published experiences with SBRT to determine local control (LC) rates as a function of SBRT dose. METHODS AND MATERIALS: One hundred sixty published articles reporting LC rates after SBRT for stage I NSCLC were identified. Quality of the series was assessed by evaluating the number of patients in the study, homogeneity of the dose regimen, length of follow-up time, and reporting of LC. Clinical data including 1, 2, 3, and 5-year tumor control probabilities for stages T1, T2, and combined T1 and T2 as a function of the biological effective dose were fitted to the linear quadratic, universal survival curve, and regrowth models.
resultsForty-six studies met inclusion criteria. As measured by the goodness of fit χ
conclusionsEarly-stage NSCLC is radioresponsive when treated with SBRT or stereotactic ablative radiation therapy. A steep dose-response relationship exists with high rates of durable LC when physical doses of 43-50 Gy are delivered in 3 to 5 fractions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.